Dividend sustainability bolsters "gsk stock price forecast", as recurring income makes the equity attractive during macroeconomic slowdown concerns. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.12. Core earnings increased 7% year over year on a reported basis and 15% at a constant exchange rate (CER), driven by favorable product mix, higher royalty income and lower net finance costs during the quarter. In the latest trading week, the "gsk stock price forecast" adjusted slightly upward due to GBP/USD currency impacts on ADR performance. Currency stability adds confidence to delivering predictable quarterly results.